Core Insights - Alibaba Health reported a revenue of 16.697 billion RMB for the six months ending September 30, 2025, representing a year-on-year growth of 17% [2] - The gross profit for the same period was 4.184 billion RMB, reflecting an 18.4% increase compared to the previous year [2] - Net profit surged to 1.266 billion RMB, marking a significant year-on-year growth of 64.7% [2] - Adjusted net profit amounted to 1.356 billion RMB, which is a 38.7% increase year-on-year [2] Financial Performance - Revenue for the six months ending September 30, 2025, was 16,697,093 thousand RMB compared to 14,273,724 thousand RMB in 2024 [1] - Gross profit increased from 3,533,765 thousand RMB in 2024 to 4,183,978 thousand RMB in 2025 [1] - The net profit for the period rose from 769,048 thousand RMB in 2024 to 1,266,413 thousand RMB in 2025 [1] - Adjusted net profit increased from 977,582 thousand RMB in 2024 to 1,356,316 thousand RMB in 2025 [1] Business Growth - As of September 30, 2025, Alibaba Health's Tmall Health platform had over 56,000 merchants [1] - Self-operated business revenue reached 14.379 billion RMB, showing an 18.6% year-on-year growth [1] - The number of SKUs in online self-operated stores increased by 98.8% to 1.61 million [1]

Core Viewpoint - Alibaba Health's stock fell over 3% despite strong interim results, indicating market skepticism about future performance guidance [1] Financial Performance - Total revenue for the six months ending September 30, 2025, was 16.697 billion RMB, a year-on-year increase of 17.0% [1] - Net profit reached 1.266 billion RMB, reflecting a year-on-year growth of 64.7%, with net profit margin increasing from 5.4% to 7.6% [1] - Adjusted net profit amounted to 1.356 billion RMB, up 38.7% year-on-year [1] Future Guidance - Citigroup raised Alibaba Health's revenue growth guidance for the fiscal year 2026 to 10% to 15% [1] - The adjusted net profit growth guidance was also increased to 20% to 30% [1] - The market is expected to focus on whether the management will further adjust performance guidance in light of strong adjusted net profit growth [1]

Core Viewpoint - The report from Credit Lyonnais indicates that JD Health's performance in the first half of the year met expectations, driven by strong user growth and good performance during the 618 shopping festival [1] Financial Performance - JD Health's revenue increased by 24.5% year-on-year to 35.3 billion yuan [1] - Earnings before interest and taxes (EBIT) rose by 57% year-on-year to 2.5 billion yuan [1] Market Trends - There has been a shift in demand for original research drugs from hospitals to outpatient settings, contributing to an increase in drug sales [1] Future Outlook - Credit Lyonnais raised JD Health's net profit forecasts for 2025 and 2026 by 15% and 13% respectively [1] - The target price for JD Health was increased from 56 HKD to 64 HKD, maintaining an "outperform" rating [1]

Group 1 - JD Health (6618.HK) saw its stock price rise over 12% to HKD 61.5, reaching a new high since March 2023 [1] - The company reported a revenue of RMB 35.29 billion for the first half of the year, representing a year-on-year growth of 24.5% [1] - Net profit for the same period was RMB 2.596 billion, with a year-on-year increase of 27.5% [1] Group 2 - The gross profit margin improved from 23.6% in the same period last year to 25.2%, primarily due to changes in the revenue mix [1] - As of the end of June, the number of annual active users exceeded 200 million, with an average of over 500,000 consultations per day in the first half of the year [1]